Drug
Ocu410
Ocu410: highest development phase Phase 1/2, developed by Ocugen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ocugen
Trials
| Drug | Phase | Indication |
|---|---|---|
| OCU410 NCT06018558 | Phase 1/2 | Geographic Atrophy |
Latest
No recent events.
Follow Ocu410 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.